Graves Disease Clinical Trials
9 recruiting trials for Graves Disease. Eligibility criteria explained in plain English.
TrialFinderData lists 9 Graves Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Early Phase 1 is the largest group at 50% (2 studies); the largest phase groups are Early Phase 1: 2, Phase 1: 1, Phase 4: 1.
Research is led by Shanghai Zhongshan Hospital (2), Royal Berkshire NHS Foundation Trust (1), University of Ulm (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Thyroid artery embolization (procedure, 1 trial), followed by Oral Glucose Tolerance Test, allogenic anti-CD19/BCMA CAR-T.
Track Graves Disease trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Thyroid Artery Goitre Embolization Trial A Pilot Study Investigating Thyroid Artery Embolisation as a Treatment for...
Large non-cancerous thyroid nodules (lumps in the thyroid gland) can cause pressure or discomfort in the neck or cosmetic issues. The standard treatment options include...
Impact of Thyroid Hormones on Human Glucose and Energy Metabolism
The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism. Patients will be included in whom thyroid hormone...
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
Graves' disease is an autoimmune thyroid disorder in which autoantibodies against the thyroid-stimulating hormone receptor (TRAb) lead to excessive thyroid hormone production and...
A Study of GensSci098 in Subjects With Graves' Disease
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
Prospective Evaluation of OptiThyDose
The aim of this multicentric, randomised, two-arms and single-blinded clinical trial is to prospectively evaluate OptiThyDose for Congenital hypothyroidism (CH) and Graves'...
In Vivo CAR-T for Refractory Graves' Disease
Graves' disease is an autoimmune thyroid disorder characterized by the production of autoantibodies against the thyroid-stimulating hormone receptor (TRAb), leading to excessive...
A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
This study was a prospective follow-up study of newly diagnosed and relapsed Graves' disease patients in the Endocrinology Clinic of the First Affiliated Hospital of China Medical...
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in...
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the...
Explore Other Conditions
Frequently Asked Questions
There are currently 9 clinical trials for Graves Disease, with 9 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Graves Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Graves Disease, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.